These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 1182332)
1. III. Views of the filter manufacturers on the regulations. Cole JC Bull Parenter Drug Assoc; 1975; 29(5):222-6. PubMed ID: 1182332 [No Abstract] [Full Text] [Related]
2. II. Views of the pharmaceutical industry on the regulations. Newmark H Bull Parenter Drug Assoc; 1975; 29(5):218-21. PubMed ID: 1182331 [No Abstract] [Full Text] [Related]
3. IV. Fiber shedding properties of depth filter media for sterile filtration. Dwyer JL Bull Parenter Drug Assoc; 1975; 29(5):227-37. PubMed ID: 1182333 [No Abstract] [Full Text] [Related]
4. I. Federal regulations concerning use of asbestos filters in manufacturing parenteral drugs. Casola AR Bull Parenter Drug Assoc; 1975; 29(5):216-8. PubMed ID: 1182330 [No Abstract] [Full Text] [Related]
5. Asbestos and glass fiber regulations. Introduction by panel moderator. Elias WE Bull Parenter Drug Assoc; 1975; 29(5):215. PubMed ID: 1182329 [No Abstract] [Full Text] [Related]
7. FDA regulations and guidelines. Rothschild A J Parenter Sci Technol; 1990; 44(1):26-9. PubMed ID: 2313489 [No Abstract] [Full Text] [Related]
8. [Drug problems and the Common Market. Personal views]. Andersen AH Ugeskr Laeger; 1973 Jun; 135(25):1300-1. PubMed ID: 4800706 [No Abstract] [Full Text] [Related]
9. Producer industry views on the AVMA legislative initiative. Keeling J J Am Vet Med Assoc; 1993 May; 202(10):1679-80;discussion 1684-92. PubMed ID: 8514583 [No Abstract] [Full Text] [Related]
10. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
11. Labeling regulations: 'prescribe as directed'. Regier H J Leg Med (N Y); 1974; 2(5):48-51. PubMed ID: 4548706 [No Abstract] [Full Text] [Related]
13. Supplements and other changes to an approved application. Final rule. Food and Drug Administration, HHS Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041 [TBL] [Abstract][Full Text] [Related]
14. Drug development history, "overview," and what are GCPs? Heilman RD Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867 [TBL] [Abstract][Full Text] [Related]
15. The new Restatement (Third) of Torts--shelter from the product liability storm for pharmaceutical companies and medical device manufacturers? Wagner MJ; Peterson LL Food Drug Law J; 1998; 53(2):225-42. PubMed ID: 10346683 [No Abstract] [Full Text] [Related]
16. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule. Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526 [TBL] [Abstract][Full Text] [Related]
17. Proposed current good manufacturing practice and supplemental regulations. Korun FD Bull Parenter Drug Assoc; 1976; 30(3):139-42. PubMed ID: 1268432 [No Abstract] [Full Text] [Related]
18. Off label drug promotion. Body Posit; 1998 Oct; 11(10):11. PubMed ID: 11365909 [TBL] [Abstract][Full Text] [Related]
19. Food processor views on the AVMA extra-label drug use legislative initiative. Crawford LM J Am Vet Med Assoc; 1993 May; 202(10):1682-3;discussion 1684-92. PubMed ID: 8514585 [No Abstract] [Full Text] [Related]
20. State legislation: effects on drug programs in industry. Angarola RT; Rodriguez SN NIDA Res Monogr; 1989; 91():305-17. PubMed ID: 2509932 [No Abstract] [Full Text] [Related] [Next] [New Search]